AU2018205484B2 - Therapeutic anti-lgE antibodies and methods and compositions thereof - Google Patents

Therapeutic anti-lgE antibodies and methods and compositions thereof Download PDF

Info

Publication number
AU2018205484B2
AU2018205484B2 AU2018205484A AU2018205484A AU2018205484B2 AU 2018205484 B2 AU2018205484 B2 AU 2018205484B2 AU 2018205484 A AU2018205484 A AU 2018205484A AU 2018205484 A AU2018205484 A AU 2018205484A AU 2018205484 B2 AU2018205484 B2 AU 2018205484B2
Authority
AU
Australia
Prior art keywords
ser
val
thr
leu
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018205484A
Other languages
English (en)
Other versions
AU2018205484A1 (en
Inventor
Andrew Saxon
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixal Inc
University of California San Diego UCSD
Original Assignee
Sixal Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018205484(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sixal Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Sixal Inc
Publication of AU2018205484A1 publication Critical patent/AU2018205484A1/en
Application granted granted Critical
Publication of AU2018205484B2 publication Critical patent/AU2018205484B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2018205484A 2017-01-06 2018-01-05 Therapeutic anti-lgE antibodies and methods and compositions thereof Active AU2018205484B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Publications (2)

Publication Number Publication Date
AU2018205484A1 AU2018205484A1 (en) 2019-08-01
AU2018205484B2 true AU2018205484B2 (en) 2024-11-21

Family

ID=62789396

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018205484A Active AU2018205484B2 (en) 2017-01-06 2018-01-05 Therapeutic anti-lgE antibodies and methods and compositions thereof

Country Status (6)

Country Link
US (2) US11518818B2 (enExample)
EP (1) EP3565587A4 (enExample)
JP (2) JP7128191B2 (enExample)
AU (1) AU2018205484B2 (enExample)
CA (1) CA3049967C (enExample)
WO (1) WO2018129248A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
CN1418222A (zh) 2000-01-14 2003-05-14 第一制药株式会社 新的肽以及使用该肽的筛选方法
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2407485T1 (sl) * 2003-02-01 2016-09-30 Tanox, Inc. Visoko afinitetna anti-humana protitelesa IgE
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
EP2511299A1 (en) * 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
TWI542598B (zh) * 2014-06-17 2016-07-21 中央研究院 交聯B淋巴球之CD23但不致敏肥大細胞的人源化抗-IgE抗體
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes

Also Published As

Publication number Publication date
US20230090487A1 (en) 2023-03-23
JP7461420B2 (ja) 2024-04-03
US11518818B2 (en) 2022-12-06
WO2018129248A1 (en) 2018-07-12
CA3049967C (en) 2024-10-01
JP2022172170A (ja) 2022-11-15
US20190322766A1 (en) 2019-10-24
CA3049967A1 (en) 2018-07-12
EP3565587A1 (en) 2019-11-13
EP3565587A4 (en) 2020-12-16
JP7128191B2 (ja) 2022-08-30
AU2018205484A1 (en) 2019-08-01
JP2020505334A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
US12398200B2 (en) Anti-allergen antibodies
JP6397938B2 (ja) Ｂリンパ球のＣＤ２３と架橋するが肥満細胞を感作しないヒト化抗ＩｇＥ抗体
AU2022229993A9 (en) Pharmaceutical composition containing anti-tslp antibody
CN111560071A (zh) 对il-21具有特异性的结合分子及其用途
CN109562167A (zh) 联合治疗
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
JP2022500457A (ja) Ｉｌ−１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
WO2023061390A1 (en) Treatment of ige-mediated diseases
RS66573B1 (sr) Anti-par-2 antitela i metode njihove upotrebe
JP2025093954A (ja) ヒト化抗－ｃ５ａ抗体
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
CN104039832A (zh) 抗磷酰胆碱的新抗体
US10513561B2 (en) Anti-MYL9 antibody
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2021142276A1 (en) Human antibodies to rift valley fever virus
US20230090487A1 (en) Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereof
JP2022172170A5 (enExample)
US20240026035A1 (en) Human ige monoclonal antibodies to antibodies to alpha-gal (galactose-a-1,3-galactose) and uses therefor
TW202513582A (zh) 過敏疾病的預防或治療藥
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
KR20240134385A (ko) 항-성장 분화 인자 15의 항체 분자 및 그의 응용

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)